Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,947,558
  • Shares Outstanding, K 166,351
  • Annual Sales, $ 2,594 M
  • Annual Income, $ 236,000 K
  • 60-Month Beta 0.49
  • Price/Sales 4.17
  • Price/Cash Flow 21.85
  • Price/Book 4.66
Trade RDY with:

Options Overview Details

View History
  • Implied Volatility 26.80%
  • Historical Volatility 21.33%
  • IV Percentile 14%
  • IV Rank 16.49%
  • IV High 62.02% on 03/23/21
  • IV Low 19.84% on 08/10/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 129

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.62
  • Growth Rate Est. (year over year) +161,029.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.10 +9.37%
on 08/26/21
67.76 -3.00%
on 09/15/21
+4.40 (+7.17%)
since 08/20/21
3-Month
60.10 +9.37%
on 08/26/21
75.50 -12.94%
on 07/02/21
-5.96 (-8.31%)
since 06/22/21
52-Week
57.54 +14.23%
on 03/18/21
75.50 -12.94%
on 07/02/21
-4.28 (-6.11%)
since 09/22/20

Most Recent Stories

More News
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.

RDY : 65.62 (-0.29%)
IRWD : 12.68 (+0.08%)
ESALY : 76.1300 (-1.04%)
CTXR : 2.14 (+6.47%)
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold

BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.

RDY : 65.62 (-0.29%)
ENDP : 3.02 (+9.42%)
BMRN : 79.59 (+1.84%)
SYBX : 3.52 (-1.40%)
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of...

CTXR : 2.14 (+6.47%)
RDY : 65.62 (-0.29%)
Dr. Reddy's Laboratories Announces the Launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Chlordiazepoxide...

RDY : 65.62 (-0.29%)
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021...

RDY : 65.62 (-0.29%)
TEVA : 8.78 (+1.15%)
AMPH : 18.59 (+0.76%)
BHC : 28.76 (+1.95%)
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock...

RDY : 65.62 (-0.29%)
TEVA : 8.78 (+1.15%)
VRTX : 185.02 (-0.42%)
AMRN : 5.28 (+2.92%)
Dr. Reddy's Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter known as "Dr. Reddy's"), announced today that it has entered into a definitive asset purchase agreement,...

BDSI : 3.55 (-11.25%)
RDY : 65.62 (-0.29%)
Dr. Reddy's Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve(R) in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the re-launch of over-the-counter...

RDY : 65.62 (-0.29%)
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

RDY : 65.62 (-0.29%)
RGEN : 312.65 (-0.49%)
CORT : 20.40 (+0.74%)
NBRV : 1.1800 (+4.42%)
Dr. Reddy's Laboratories Announces Filing of Annual Report on Form 20-F

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced that its Annual Report on Form...

RDY : 65.62 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

3rd Resistance Point 66.90
2nd Resistance Point 66.56
1st Resistance Point 66.19
Last Price 65.62
1st Support Level 65.48
2nd Support Level 65.14
3rd Support Level 64.77

See More

52-Week High 75.50
Fibonacci 61.8% 68.64
Fibonacci 50% 66.52
Last Price 65.62
Fibonacci 38.2% 64.40
52-Week Low 57.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar